|会社名||Global Blood Therapeutics Inc （グロ―バル・ブラッド・セラピュ―ティクス）|
|分野（sector）||Health Care ヘルスケア|
|業種||バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care）|
|概要||事業概要 グローバル・ブラッド・セラピューティクス（Global Blood Therapeutics Inc.）は臨床段階のバイオ医薬品会社である。同社は、血液ベースの障害を治療するための治療薬の発見・開発・商業化に従事する。同社は鎌状赤血球症（SCD）の経口一日1回治療薬として、初期製品候補であるGBT440を開発している。同社は成人および青年期のSCD患者のGBT440の第III相臨床試験において、SCDのGBT440を評価する。GBT440は、RBC鎌状赤血球の根底にある機構である異常なヘモグロビン重合を阻害する。また、遺伝性血管浮腫（HAE）を対象としたその他の研究開発活動を行う。GBT440は、ヘモグロビンのアルファ鎖に結合することにより、ヘモグロビンの酸素に対する親和性を増加させる治験薬である。GBT440は鎌状赤血球ヘモグロビン（HbS）を酸素化状態で保持し、重合に関与しないことが観察されている。 グロ―バル・ブラッド・セラピュ―ティクスは米国のバイオ医薬品企業。臨床段階で、血液疾患に関する医薬品の発見、開発、商業化に従事する。薬剤候補に鎌状赤血球病(SCD)予防薬「GBT440」があり、1日1回の経口投与で治療する。激痛や多臓器損傷をもたらすSCDに焦点を当て、赤血球のメカニズムを考慮した治療薬を開発する。本社はカリフォルニア州。 Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.|
|本社所在地||171 Oyster Point Boulevard Suite 300 South San Francisco CA 94080 USA|
|代表者氏名||Ted W. Love テッド・W・ラブ|
|代表者役職名||President Chief Executive Officer Director 社長兼最高経営責任者（CEO）|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Global Blood Therapeutics Inc revenues was not reported. Net loss increased 74% to $81.9M. Higher net loss reflects Research and Development Expense increase of 66% to $54.8M (expense) Stock-based Compensation in SGA increase from $2.7M to $8.8M (expense) General and administrative increase of 50% to $14.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.15 to -$1.65.|
DSC Advisors, L.P. Buys AmerisourceBergen Corp, eHealth Inc, Global Blood Therapeutics Inc, ... 2021/08/24 19:38:05 GuruFocus
Related Stocks: ABC , EHTH , GBT , BMY , EAR , COMS , X , SIL , FTCV , EOG , 9DA , SHW , SLV , UBER , ADP , CS ,
Global Blood Therapeutics, Inc. 2021 Q2 - Results - Earnings Call Presentation 2021/08/05 17:49:54 Seeking Alpha
Global Blood Shoots 17% Higher As Q2 Earnings Beat Estimates; Analyst Upgrades Stock 2021/08/04 16:50:51 Benzinga
Global Blood Therapeutics Inc (NASDAQ: GBT ) reported Q2 Oxbryta (voxelotor) sales of $47.55 million , +51% Y/Y, beating the consensus of $43.84 million. On a sequential basis, sales increased 22%, primarily driven by patient demand. Oxbryta (voxelotor) is an oral, once-daily therapy for sickle cell disease (SCD) patients. Oxbryta works by increasing hemoglobin''s affinity for oxygen. GBT recorded approximately 925 new prescriptions Full story available on Benzinga.com
Truist upgrades Global Blood Therapeutics to buy on Q2 2021 results; shares up 17% 2021/08/04 13:57:01 Seeking Alpha
Thinking about buying stock in Global Blood Therapeutics, Cerus Corp, Coursera, Agrify Corp, or Invitae Corp? 2021/08/04 12:45:00 Benzinga
NEW YORK , Aug. 4, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GBT, CERS, COUR, AGFY, and NVTA. Full story available on Benzinga.com
Global Blood Therapeutics Consensus Indicates Potential 128.6% Upside 2021/07/07 11:28:01 DirectorsTalk
Global Blood Therapeutics found using ticker (GBT) have now 19 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 138 and 40 with a mean TP of 78.63. Given that the stocks previous close was at 34.39 this indicates there is a potential upside of 128.6%. The 50 day MA is 37.64 and the 200 day MA is 42.48. The market capitalisation for the company is $2,082m. You can visit the company''s website by visiting: /> [stock_market_widget type="chart" symbol="GBT" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Global Blood Therapeutics, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD.
Global Blood Therapeutics: Return On Capital Employed Insights 2021/07/01 15:05:45 Benzinga
During Q1, Global Blood Therapeutics ''s (NASDAQ: GBT ) reported sales totaled $39.04 million. Despite a 20.83% in earnings, the company posted a loss of $71.03 million. Global Blood Therapeutics collected $41.30 million in revenue during Q4, but reported earnings showed a $58.79 million loss. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth Full story available on Benzinga.com
Why Global Blood Therapeutics Moved Higher Wednesday 2021/07/01 11:59:00 The Motley Fool
The pharmaceutical company, which specializes in therapies to fight sickle cell disease, rose nearly 8% on Wednesday.
2021 Contrast Agents Market Report- Global Industry Analysis | Bayer AG, GE Healthcare LLC, Guerbet SA 2021/06/30 08:42:17 Jumbo News
ReportsnReports added Contrast Agents Market Research Report created by Report Consultant, which offers detailed insights, revenue details, and other information regarding the global market, and the various trends, drivers, restraints, opportunities, and market till 2028. Contrast Agents Market Report offers detailed information regarding the leading key players operating in the market, their financials, supply chain 
Global Blood Therapeutics downgraded to neutral from overweight at JPMorgan, price target cut to $36 from $70 2021/06/28 15:29:01 MarketWatch
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.
UTHSC College of Nursing and Sickle Cell Foundation of Tennessee initiatives receive $50K grants 2021/06/16 19:19:39 Business Journals
The grants came from Global Blood Therapeutics Inc. (GBT), a San Francisco-based biopharmaceutical company, which distributed $450,000 in funds to U.S.-based community organizations.
Global Blood Therapeutics, Inc.: GBT''s Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine (PIM) Designation in the UK 2021/06/14 11:05:00 FinanzNachrichten
SOUTH SAN FRANCISCO, Calif. and LONDON, June 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company dedicated to the discovery, development an
GBT''s Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine (PIM) Designation in the UK 2021/06/14 11:00:00 Benzinga
SOUTH SAN FRANCISCO, Calif. and LONDON, June 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT ), a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments for underserved patient communities, announced today that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom has granted a Promising Innovative Medicine (PIM) designation for voxelotor for the potential treatment of hemolytic anemia in adults and adolescent patients 12 years of age and older with sickle cell disease (SCD). Following a review by the MHRA, PIM designations are given to promising treatments that are likely to offer a major advantage for patients and are an early indication that the treatment is a promising candidate for the Early Access to Medicines Scheme (EAMS). For the MHRA to grant a PIM designation, the product must meet each of the following three criteria: The condition should be life-threatening or seriously debilitating with high unmet need, meaning there is no method of treatment, diagnosis or prevention available, or existing methods have serious limitations.
Global Blood Therapeutics, Inc.: New Data Supporting the Potential Use of Oxbryta (voxelotor) in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at European Hematology Association 2021 Virtual Congress 2021/06/11 07:17:00 FinanzNachrichten
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies Demonstrated Sustained Improvements in Hemoglobin with Oxbryta Consistent with Results from the Ph
New Data Supporting the Potential Use of Oxbryta (voxelotor) in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at European Hematology Association 2021 Virtual Congress 2021/06/11 07:00:00 Wallstreet:Online
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies Demonstrated Sustained Improvements in Hemoglobin with Oxbryta Consistent with Results from the Phase 3 HOPE Study SOUTH SAN FRANCISCO, Calif., June 11, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced new data from the Phase 2a HOPE-KIDS 1 Study that
関連キーワード （バイオテクノロジ―_メディカルリサ―チ 米国株 グロ―バル・ブラッド・セラピュ―ティクス GBT Global Blood Therapeutics Inc.）